KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Oct 23, 2026 >>  ABB India 6140  [ -4.95% ]  ACC 1158.55  [ -2.38% ]  Ambuja Cements 358  [ 0.69% ]  Asian Paints 2305  [ 0.59% ]  Axis Bank 1214.05  [ 0.48% ]  Bajaj Auto 10080  [ -0.52% ]  Bank of Baroda 231  [ -1.89% ]  Bharti Airtel 1890  [ -0.52% ]  Bharat Heavy 387  [ -2.84% ]  Bharat Petroleum 281.25  [ -1.83% ]  Britannia Industries 4547.8  [ -1.99% ]  Cipla 1337  [ 0.53% ]  Coal India 397.75  [ -1.08% ]  Colgate Palm 1604  [ -4.81% ]  Dabur India 366  [ -0.85% ]  DLF 653.55  [ -1.66% ]  Dr. Reddy's Lab. 1224.5  [ -1.17% ]  GAIL (India) 163.3  [ -2.74% ]  Grasim Industries 2898  [ 0.77% ]  HCL Technologies 1424  [ -0.14% ]  HDFC Bank 692.1  [ -0.17% ]  Hero MotoCorp 5035.35  [ -1.64% ]  Hindustan Unilever 1820  [ -0.76% ]  Hindalco Industries 860.5  [ -3.10% ]  ICICI Bank 1395  [ 0.01% ]  Indian Hotels Co. 784  [ 0.09% ]  IndusInd Bank 835  [ -1.76% ]  Infosys 1154.5  [ 0.30% ]  ITC 257.2  [ -0.41% ]  Jindal Steel 1012  [ -1.72% ]  Kotak Mahindra Bank 430.1  [ -1.70% ]  L&T 3645  [ 1.25% ]  Lupin 1925  [ -0.16% ]  Mahi. & Mahi 2848  [ -0.23% ]  Maruti Suzuki India 11258.95  [ 0.54% ]  MTNL 22.82  [ -7.05% ]  Nestle India 1173.45  [ -1.39% ]  NIIT 73.49  [ -5.69% ]  NMDC 66.3  [ -3.77% ]  NTPC 298  [ -1.28% ]  ONGC 226  [ 0.51% ]  Punj. NationlBak 120.35  [ -1.59% ]  Power Grid Corpn. 247.2  [ -0.16% ]  Reliance Industries 1190  [ 1.19% ]  SBI 957  [ -1.17% ]  Vedanta 226  [ -3.00% ]  Shipping Corpn. 237.95  [ -5.63% ]  Sun Pharmaceutical 1743  [ -0.62% ]  Tata Chemicals 575.5  [ -3.12% ]  Tata Consumer 960  [ -0.31% ]  Tata Motors Passenge 265.45  [ -1.50% ]  Tata Steel 167.25  [ -3.21% ]  Tata Power Co. 346  [ -2.12% ]  Tata Consult. Serv. 2528  [ 1.00% ]  Tech Mahindra 1789.4  [ -1.95% ]  UltraTech Cement 11066  [ 0.83% ]  United Spirits 1250.45  [ -2.45% ]  Wipro 189.75  [ -0.13% ]  Zee Entertainment 65.45  [ -4.42% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

VENUS REMEDIES LTD.

23 October 2026 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE411B01019 BSE Code / NSE Code 526953 / VENUSREM Book Value (Rs.) 513.74 Face Value 10.00
Bookclosure 07/08/2026 52Week High 2044 EPS 76.90 P/E 18.26
Market Cap. 1877.13 Cr. 52Week Low 432 P/BV / Div Yield (%) 2.73 / 0.71 Market Lot 1.00
Security Type Other

NOTES TO ACCOUNTS

You can view the entire text of Notes to accounts of the company for the latest year
Year End :2026-03 

14.2 Rights, Preference and restriction attached to shares

The Company has one class of equity shares having a par value of C 10 each. Each shareholder is eligible for one vote per share held. The dividend proposed by the board of directors are subject to shareholders approval in ensuing AGM except in case of interim dividend. In the event of liquidation the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all the preferential amount in proportion to their shareholding.

ii) Financial risk management

The Company has exposure to the following risks arising from financial instruments:

A. Credit Risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's receivables from customers and investments in debt securities. The carrying amount of financial assets represents the maximum credit exposure.

• Trade receivables

• Other financial assets

• Other bank balances

Credit risk management

The Company assesses and manages credit risk based on internal credit rating system, continuously monitoring defaults of customers and other counterparties, identified either individually or by the company, and incorporates this information into its credit risk controls. Internal credit rating is performed for each class of financial instruments with different characteristics. The Company assigns the following credit ratings to each class of financial assets based on the assumptions, inputs and factors specific to the class of financial assets.

• Low

• Medium

• High

Trade receivables

The Company closely monitors the credit-worthiness of the debtors through internal systems that are configured to define credit limits of customers, thereby, limiting the credit risk to pre-calculated amounts. The Company assesses increase in credit risk on an ongoing basis for amounts receivable that become past due and default is considered to have occurred when amounts receivable become past due one year.

Other financial assets measured at amortised cost

Other financial assets measured at amortised cost includes loans and advances to employees, security deposits and others. Credit risk related to these other financial assets is managed by monitoring the recoverability of such amounts continuously, while at the same time internal control system in place ensure the amounts are within defined limits.

B. Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities. Management monitors rolling forecasts of the Company's liquidity position and cash and cash equivalents on the basis of expected cash flows. The Company takes into account the liquidity of the market in which the company operates.

Maturities of financial liabilities

The tables below analyse the Company's financial liabilities into relevant maturity of the Company based on their contractual maturities for all non-derivative financial liabilities.

(ii) Foreign currency sensitivity

The following tables demonstrate the sensitivity to a reasonably possible change in exchange rates of USD, EURO and GBP with all other variables held constant. The impact on the Company's profit before tax is due to changes in the fair value of monetary assets and liabilities including non-designated foreign currency derivatives. Although the derivatives have not been designated in a hedge relationship they act as an economic hedge and will offset the underlying transactions when they occur. Accordingly, no sensitivity analysis in respect of such loans is given. The Company's exposure to foreign currency changes for all other currencies is not material.

C. Market risk

Market risk is the risk that changes in market prices - such as foreign exchange rates interest rates and equity prices - will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters while optimizing the return.

a. Foreign currency risk

The Company is exposed to foreign exchange risk arising from foreign currency transactions primarily with respect to the US Dollar, EURO and GBP. Foreign exchange risk arises from recognised assets and liabilities denominated in a currency that is not the functional currency of the Company.

• directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries); or

• provide any guarantee security or the like to or on behalf of the Ultimate Beneficiaries.

• The Company has not received any fund from any person or entity including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

H directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or

H provide any guarantee security or the like on behalf of the Ultimate Beneficiaries.

• The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act 1961 (such as search or survey or any other relevant provisions of the Income Tax Act 1961.

• Since the company does not have any working capital limit or borrowings from any bank of financial institution the Company has not been declared a wilful defaulter by any bank or financial institution or other lender (as defined under the Companies Act 2013) or consortium thereof in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India.

• The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

• The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Companies Act 2013 read with the Companies (Restriction on number of Layers) Rules 2017.

39a. Decrease in current ratio is mainly due to increase in current liabilities and better utilization of working capital during the year. 39b. Increase in ratio is due to higher sales and efficient utilization of working capital as compared to previous year.

39c. Increase in ROE is mainly attributable to higher profitability during the year resulting in improved returns to shareholders.

39d. Net profit ratio improved due to increase in revenue, better cost control and improved operational efficiency during the year 39e. Increase in ROCE is due to higher earnings before interest and tax and efficient utilization of capital employed.

NOTE: 40

During the year the company has undertaken a review of all Property Plant & Equipment in line with the requirements of Ind AS - 36 on "Impairment of Assets". Based on such review no provision for impairment is required to be recognized during the year.

NOTE: 41

The Company has received outstanding income tax refunds, including interest, amounting to H1,096.79 lakhs for AY 2010-11,2013-14, 2023-24, and 2025-26. The balance refund for AY 2011-12 and AY 2012-13 remain under litigation.

NOTE: 42 OTHER STATUTORY INFORMATION

• The Company does not have any Benami property where any proceeding has been initiated or pending against the Company for holding any Benami property.

• The Company does not have any transactions with struck-off companies under Section 248 of the Companies Act 2013 or Section 560 of the Companies Act 1956

• The Company has not traded or invested in Cryptocurrency or Virtual Currency during the financial year.

• The Company has not advanced or loaned or invested funds to any other person or entity including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

NOTE: 45

The company operates only in one business segment viz "Pharmaceutical Formulation" and is engaged in manufacturing and trading of medicines.

NOTE: 46 EVENTS AFTER THE REPORTING PERIOD

There are no subsequent events that occur after the reporting period.

NOTE: 47

The standalone financial statements for the year ended 31st March 2026 were approved by the board of directors on 26th May 2026. NOTE: 48

The previous year figures have been regrouped/ reclassified wherever necessary to Confirm to the current year presentation.